Bowen Acquisition Corp (BOWN) has released an update to notify the public and investors about an entry into a material definitive agreement.
On January 18, 2024, Bowen Acquisition Corp, its subsidiary Bowen Merger Sub, Shenzhen Qianzhi BioTechnology Co. Ltd., and Qianzhi Group Holding Limited entered into an Agreement and Plan of Reorganization to facilitate a business combination. The agreement outlined a merger in which the merger sub will merge with NewCo, making NewCo a wholly owned subsidiary of Parent, and NewCo shareholders will receive shares in Parent. Preceding this, the Company restructured to become a wholly owned subsidiary of NewCo. The transaction is subject to various approvals and conditions, including shareholder approvals and Nasdaq listing of the Parent Ordinary Shares, with the closing expected in 2024. The Company, a biotech firm specializing in ozonated, herbal-infused health products, believes its disinfectants are superior to traditional alternatives. The agreement also includes earnout considerations, representations, warranties, and indemnification clauses.
For further insights into BOWN stock, check out TipRanks’ Stock Analysis page.
